Paris - Delayed Quote EUR

Aelis Farma SA (AELIS.PA)

0.7200 -0.0030 (-0.41%)

As of 9:00:24 AM GMT+1. Market Open.

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Name	Title	Pay	Exercised	Year Born
Dr. Pier Vincenzo Piazza M.D., Ph.D.	CEO & Director	458.61k	--	1961
Stephanie Monlezun	Chief Operating Officer	--	--	--

1 rue Lafaurie de Monbadon

Bordeaux, 33000

France

33 5 54 54 23 27 https://www.aelisfarma.com

Sector:: Healthcare
Industry:
Full Time Employees:: 14

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat other CB1-dependent diseases, including several orphan diseases. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.

Aelis Farma SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

September 15, 2026 at 3:30 PM UTC

Aelis Farma SA Earnings Date

Recent Events Information Not Available

U.S. markets open in 4h 22m

Aelis Farma SA (AELIS.PA)

Key Executives

Aelis Farma SA

Description

Corporate Governance

Upcoming Events

Recent Events

Related Tickers